Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects. by Giovannini, S et al.
Giovannini et al. Cardiovasc Diabetol  (2017) 16:99 
DOI 10.1186/s12933-017-0581-z
ORIGINAL INVESTIGATION
Serum high mobility group box-1 
and osteoprotegerin levels are associated 
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Abstract 
Background: High mobility group box-1 (HMGB-1) is a nuclear protein also acting as inflammatory mediator, whilst 
osteoprotegerin (OPG), member of tumor necrosis factor receptor superfamily, is indicated as marker of vascular cal-
cification. Peripheral artery disease (PAD) and type 2 diabetes (T2D) are clinical conditions characterized by elevated 
serum inflammatory markers and vascular calcification enhancement. The aim of this study was to investigate the 
potential role of HMGB-1, OPG and several inflammatory mediators such as C-reactive protein (HsCRP), tumor necrosis 
factor-alpha and interleukin-6 (IL-6) on the presence and severity of peripheral artery disease in patients with T2D.
Methods: In this retrospective observational study, we have analyzed HMGB-1, OPG and inflammatory cytokines 
serum levels in 1393 type 2 diabetic patients with PAD and without PAD (WPAD).
Results: HMGB-1 (7.89 ± 15.23 ng/mL), OPG (6.54 ± 7.76 pmol/L), HsCRP (15.6 ± 14.4 mg/L) and IL-6 
(56.1 ± 28.6 pg/mL) serum levels were significantly higher in patients with PAD than in those WPAD (3.02 ± 8.12 ng/
mL, P ˂ 0.001; 2.98 ± 2.01 pmol/L, P < 0.001; 7.05 ± 4.4 mg/L, P < 0.001; 37.5 ± 20.2 pg/mL, P < 0.001 respectively). 
Moreover HMGB-1 (P < 0.001), OPG (P < 0.001), HsCRP (P < 0.001) and IL-6 (P < 0.001) serum levels were positively cor-
related with clinical severity of PAD. HMGB-1 (adjusted OR 12.32; 95% CI 3.56–23.54, P = 0.023) and OPG (adjusted OR 
3.53; 95% CI 1.54–6.15, P = 0.019) resulted independent determinants of PAD in patients with T2D after adjusting for 
the conventional cardiovascular risk factor and established inflammatory mediators.
Conclusions: In T2D patients HMGB-1 and OPG serum levels are higher in patients affected by PAD  
and independently associated with its occurrence and clinical severity.
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Background
Peripheral arterial disease (PAD) is a clinical manifesta-
tion of systemic atherosclerosis affecting ten millions of 
people worldwide. The frequency of PAD seems to be 
increasing rapidly in in low-income and middle-income 
countries, and traditional cardiovascular risk factors of 
diabetes, age, smoking, dyslipidemia, and hypertension 
are likely to be the principal risk factors driving the epi-
demiological transition [1]. Atherosclerosis is now under-
stood to be an inflammatory disease [2]. Particularly in 
patients with type 2 diabetes mellitus (T2D) the main 
mechanisms supposed involved in atherosclerotic disease 
progression are the decrease of nitric oxide production, 
the enhancement of oxidative stress, and the impairment 
of endothelial progenitor cell function [3]. Also in T2D 
inflammatory circulating molecules as C-reactive protein 
(HsCRP), tumor necrosis factor-alpha (TNF-alpha), and 
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interleukin-6 (IL-6), together with abnormal endothelial 
expression of intercellular adhesion molecule-1 (ICAM-
1) and vascular cell adhesion molecule-1 (VCAM-1) 
support a low-grade chronic state of inflammation and 
contribute to progression of disease and its complica-
tions providing prognostic information on clinical out-
comes [4].
Several studies have shown that high mobility group 
box-1 (HMGB-1), a nuclear protein regulating gene 
expression, induces an inflammatory response dur-
ing vascular damage [5]. HMGB-1 is a nuclear pro-
tein that has not only a role in the regulation of gene 
expression but also can activate pro-inflammatory 
responses after being passively released by damaged and 
necrotic cells or actively secreted by stimulated con-
ditional innate immune cells such as endothelial cells 
[6, 7]. Moreover the release of HMGB-1 induced by 
HsCRP, one of the most sensitive biomarker of inflam-
mation, induces, amplifies, and extends the inflamma-
tory processes surrounding the atherosclerotic lesions 
[8]. Further HMGB-1 is not only released in response to 
pro-inflammatory stimuli, but itself causes the secretion 
of inflammatory molecules such as IL-6 and TNF-alpha 
by neutrophils and macrophages [9]. HMGB-1 has been 
shown be an inflammatory mediator promoting chronic 
inflammation and neovascularization in diabetes [10]. 
In addition, an associations between level of HMGB-1 
and clinical complications of diabetes has been reported. 
Particularly a recent study showed that serum HMGB-1 
is positively related to HbA1c level and is an independ-
ent predictor for coronary artery disease in patients with 
diabetes [11]. Moreover elevated expression of this pro-
tein has been reported in the retinas of diabetic patients 
and in diabetic nephropathy [12, 13]. All together those 
findings suggest that HGMB-1 may contribute to inflam-
mation, endothelial dysfunction and atherosclerosis 
progression in diabetes mellitus [14]. Also HMGB-1 
increases osteoprotegerin (OPG) expression in osteo-
blasts and is chemotactic to osteoclasts and osteoblasts 
during endochondral ossification, such as to monocytes 
and other immune and non-immune cells [15]. OPG 
is a member of the tumor necrosis factor (TNF) recep-
tor family implied in bone turnover process, osteoporo-
sis and premature vessel calcification [16]. Interestingly 
recent studies indicate that OPG is an important regu-
latory molecule in vascular diseases, including cerebral 
atherosclerosis, and contributes to vessel calcifications in 
T2D patients, thus suggesting an its possible role in pro-
gression of atherosclerotic lesions of other vascular beds 
such as lower extremity PAD of patients affected by dia-
betes [17, 18]. At this regard clinical studies investigating 
the circulating levels of OPG in patients with PAD have 
given controversial results [19], showing some of them 
no serum OPG increase in patient with PAD [20, 21], 
and others a positive correlation between OPG circulat-
ing levels and PAD occurrence [16, 22–24]. However cur-
rently the role of OPG and its relationship with chronic 
inflammatory markers in T2D patients affecting by PAD 
remains unclear, largely unexplored in experimental and 
clinical investigations, considering that there are some 
frequently ignored aspects like polyvascular atheroscle-
rosis which might influence OPG levels [19].
The aims of our current study is to investigate the 
involvement of serum HMGB-1, OPG, HsCRP, TNF-




Diabetic patients with PAD (PAD) and diabetic controls 
without PAD (WPAD) were recruited among subjects 
consecutively admitted to the Department of Internal 
Medicine of the “A. Gemelli” Catholic University Hospi-
tal of Rome, Italy and to the Department of Medicine of 
the “St. M. Goretti” Hospital, Latina, Italy, from Novem-
ber 1, 2013, to January 30, 2017. Inclusion criteria for dia-
betic PAD patients were Caucasian race and presence of 
PAD at Fontaine’s stage II, III, or IV. Diagnosis of PAD 
was performed according to previous criteria established 
by the Ad Hoc Committee on Reporting Standards of the 
Society for Vascular Surgery and the International Soci-
ety for Cardiovascular Surgery [25, 26]. All PAD patients 
enrolled in the study (n = 569) underwent bilateral high-
resolution B-mode ultrasonography evaluation (Eco-
color-Doppler Acuson 128XP/10, Acuson, Mountain 
View, CA, USA, with an 4 MHz transducer) and had an 
ABI lower than 0.8 and. In according to the Fontaine’s 
staging system, the severity of PAD was defined in stage 
II when the patients presented claudicatio intermittens, 
stage III when they presented rest pain, and in stage IV 
when ischemic trophic lesions of the lower limbs were 
present [27]. Following the recommendations of the 
Inter-Society Consensus for the Management of Periph-
eral Arterial Disease (TASC II), patients with ischemic 
rest pain, ulcers, or gangrene, attributable to objec-
tively proven PAD, were considered affected by critical 
limb ischemia (CLI) [28]. Inclusion criteria for diabetic 
patients WPAD were Caucasian race and absence of PAD 
evaluated with ankle-brachial-index (ABI) and bilateral 
high-resolution B-mode ultrasonography. Eight hundred 
twenty-four diabetic subjects WPAD matched for age 
and gender were enrolled as controls, with an ABI ≥1 
and normal findings at bilateral high-resolution B-mode 
ultrasonography evaluation.
Exclusion criteria from the study for whole diabetic 
population (with and without PAD) were liver disease, 
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cancer, serous membrane chamber fluid, hypothyroidism, 
severe edema and osteoporosis. No one of the patients 
was taking estrogen supplements, immunosuppressive 
drugs, thyroxin, glucocorticoids, bisphosphonates and 
anticoagulants.
The presence of T2D has been confirmed by gly-
cated hemoglobin levels >5.8%, fasting blood glucose 
>126 mg/dL or by indication for insulin or anti-diabetic 
medicaments. Hypertension has been defined as sys-
tolic blood pressure >130  mmHg, diastolic blood pres-
sure >85 mmHg or indication to antihypertensive drugs. 
Hypercholesterolemia has been defined for having 
serum cholesterol >220 mg/dL or use of hypocholester-
olemic medications. Nonsmokers were indicated patients 
that had never smoked or had stopped smoking within 
≥1  year before enrollment in the study. All remaining 
patients were classified as smokers.
Approval for this study was provided by the Ethics 
Committees of the “A. Gemelli” Catholic University Hos-
pital of Rome, Italy, and “St. M. Goretti” Hospital, Latina, 
Italy. Informed consent was obtained from enrolled 
patients.
Biochemical measurements
For every patient, fast glucose, triglycerides, total choles-
terol, low and high-density lipoprotein, white blood cell 
count have been determined. Blood samples were col-
lected from all individuals involved after an overnight 
fast. Serum obtained and separated by centrifugation of 
blood samples was stored at −80 °C before every meas-
urement. Serum HMGB-1 level has been determined by a 
commercially available ELISA kit (HMGB-1 ELISA kit II; 
Shino-Test Corporation, Tokyo) according to its protocol. 
The detection limit for HMGB-1 was 0.2 ng/mL with an 
inter-assay coefficient of variation (CV) <10%. HsCRP 
levels have been determined by using a high-sensitivity 
ELISA kit (Biocheck Laboratories, Toledo, OH, USA). As 
a capture antibody we used a monoclonal mouse anti-
human OPG antibody and a biotinylated polyclonal goat 
antihuman OPG antibody (R&D systems). The intra and 
inter-assay coefficients of variation were 3.6 and 10.6%, 
respectively. The sensitivity, defined as the mean ± 3 SD 
of the 0 standard, was calculated to be 0.15  pmol/mL. 
By using the Quantikine ELISA kit (R&D Systems, Min-
neapolis, MN, USA) we have assessed serum IL-6 and 
TNF-alpha levels. For each patient, the serum levels were 
measured twice and the results were averaged.
Statistical analysis
Demographic and clinical data between the groups have 
been compared using Chi squared and t tests. HMGB-
1, OPG, HsCRP, TNF-alpha and IL-6 serum levels have 
been compared through Mann–Whitney test. Using a 
multivariate stepwise logistic regression analysis, two 
models have been tested. The first one is adjusted for tra-
ditional risk factors (all parameters are shown in Table 1), 
while HMGB-1 and OPG are have been included for test-
ing in the second model. All analyses are performed using 
the STATA version 11.0 for Windows (Statistics/Data 
Analysis, Stata Corporation, College Station, TX, USA). 
Statistical significance has been established at P < 0.05.
Results
The socio-demographic and clinical characteristics of 
diabetic patients with PAD and WPAD are summarized 
in Table 1. Diabetic PAD patients had higher blood pres-
sure values (P = 0.029) and higher CAD (P = 0.026) and 
were more often smokers (P = 0.023). There were no sig-
nificant differences between groups regarding to median 
duration of diabetes (P = 0.095), fast glucose (P = 0.856), 
glycated hemoglobin (P =  0.763), total cholesterol (TC) 
(P = 0.239), HDL-C (P = 0.329), LDL-C (P = 0.206) and 
triglyceride (P  =  0.913). Among 569 PAD patients, 63 
diabetic patients (11.1%) were subjected to only diet, 308 
(54.1%) were taking oral hypoglycemic agents and 198 
Table 1 Demographic and  clinical data of  diabetic sub-
jects with and without PAD
Data are number (%) and standard deviation (SD)
CAD coronary artery disease, HDL-C high-density lipoprotein cholesterol, LDL-C 
low-density lipoprotein cholesterol
* Statistical test performed with Student’s t test
† Chi square test for categorical values
WPAD PAD P value
(n = 824) (n = 569)
Men/female (n) 490:334 344:225 0.243†
Age (years ± SD) 71.3 ± 4.4 70.7 ± 4.3 0.647*
Smoking (current) (%) 181 (22.0) 210 (36.9) 0.023†
Hypertension (%) 335 (40.7) 355 (62.4) 0.029†
CAD (%) 275 (33.4) 297 (52.2) 0.026†
Diabetes duration (years ± SD) 12.1 ± 4.1 12.7 ± 4.9 0.095*
Total cholesterol (mmol/L) 4.97 (1.21) 4.87 (1.15) 0.239*
HDL-C (mmol/L) 1.21 (1.04) 1.23 (1.02) 0.329*
LDL-C (mmol/L) 2.96 (1.02) 2.87 (0.93) 0.206*
Triglyceride (mmol/L) 2.05 (1.54) 1.87 (0.98) 0.913*
Fast glucose (mmol/L) 6.89 (1.92) 7.01 (2.65)a 0.856*
Glycated hemoglobin (%) 7.37 (1.21) 7.24 (1.14) 0.763*
Treatment
 Diet only (%) 95 (11.5) 63 (11.1) 0.658†
 Oral agents (%) 452 (54.9) 308 (54.1) 0.341†
 Insulin therapy (%) 277 (33.6) 198 (34.8) 0.290†
PAD
 1-Fontaine’s II (%) 281 (49.4)
 2-Fontaine’s III (%) 163 (28.6)
 2-Fontaine’s IV (%) 125 (22.0)
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(34.8%) were prescribed insulin. According to the Fon-
taine’s classification 281 patients were defined as stage II, 
163 as stage III and 125 as stage IV.
The diabetic PAD patients group had higher HMGB-1 
(7.89 ± 15.23 ng/mL), OPG (6.54 ± 7.76 pmol/L), HsCRP 
(15.6 ±  14.4 mg/L) and IL-6 (56.1 ±  28.6 pg/mL) com-
pared to WPAD group (3.02  ±  8.12  ng/mL, P  <  0.001; 
2.98 ± 2.01 pmol/L, P < 0.001; 7.05 ± 4.4 mg/L, P < 0.001; 
37.5 ±  20.2  pg/mL, P  <  0.001 respectively) (Fig.  1). No 
differences in serum TNF-alpha levels were detected 
(P < 0.213).
When diabetic PAD patients were divided into two 
clinical categories, the first one consisting in patients 
affected by stable PAD (stage II, n =  281) and the sec-
ond consisting in patients affected by CLI (stage III and 
IV, n  =  288), interestingly current smoking, CAD, dia-
betes duration, TC and LDL-C were significantly and 
independently associated with CLI (Table  2). Moreover 
serum levels of pro-inflammatory cytokines were signifi-
cantly higher in diabetic PAD patients having CLI than in 
those with stable PAD (HMGB-1 8.35 ± 12.72 ng/mL vs 
4.53 ± 7.65 ng/mL, P < 0.001; OPG 7.64 ± 9.29 pmol/L vs 
3.24 ± 2.56 pmol/L, P < 0.001; HsCRP 18.1 ± 15.9 mg/L 
vs 9.3 ± 5.1 mg/L, P < 0.001; IL-6 62.1 ± 29.4 pg/mL vs 
41.5 ± 18.7 pg/mL, P < 0.001) (Fig. 2).
The multivariate logistic regression analysis showed 
that in the model 1, after adjustments for cardiovas-
cular risk factors and inflammatory cytokines, showed 
that smoking, hypertension, hyperlipidemia, TC, HDL-
C, LDL-C, HsCRP and IL-6 were independent determi-
nants for PAD occurrence in patients with T2D. When 
HMGB-1 and OPG were included in the multivariate 
analysis (model 2), HMGB-1 (adjusted OR 12.32; 95% 
CI 3.56–23.54, P =  0.023) and OPG (adjusted OR 3.53; 
95% CI 1.54–6.15, P = 0.019) are resulted independently 
associated with PAD in T2D patients and most of the 
traditional cardiovascular risk factors shown in model 1 
remained determinants of PAD even in model 2 (Table 3).
Discussion
Cross‑talk between HMGB‑1 and inflammatory molecules
The present study has demonstrated in a large popula-
tion of T2D patients that serum HMGB-1 levels are sig-
nificantly increased in PAD patients and correlated with 
clinical severity. Particularly we found that the HMGB-1 
serum levels are statistically significant higher in T2D 
patients with PAD than in diabetic control WPAD 
(P  <  0.001). Our observations are consistent with the 
study of Oozawa and collaborators, conducted in smaller 
population where few diabetic patients were compared to 
healthy controls, instead of T2D patients [29]. Our choice 
to investigate only diabetic patients has been suggested 
by the evidence that diabetes is one of the strongest pre-
dictor for critical limb ischemia occurrence [30].
Furthermore HMGB-1 serum levels increased accord-
ing to the Fontaine’s stage. In fact when diabetic PAD 
patients were divided into two clinical categories, con-
sisting in patients affected by stable PAD and in patients 
affected by CLI, HMGB-1 serum levels were signifi-
cantly higher in patients affected by CLI than stable PAD 
(P < 0.001).
In addition the present study confirmed our previous 
data showing that OPG, HsCRP and IL-6 serum lev-
els are associated with PAD (P  <  0.001, P  <  0.001 and 
P  <  0.001 respectively; Fig.  1) and gradually increase 
according to clinical severity of disease (Fig. 2). The rela-
tionship persists significant also after adjustment for 
potential confounding variables such as age, smoking 
status, hypertension, serum lipid profile, glycaemic con-
trol, and chronic inflammation. A multivariate logistic 
regression analysis demonstrate that both HMGB-1 and 
OPG remain independently associated with CLI in dia-
betic patients (model 2) and most of traditional risk fac-
tors in model 1 are determinants of CLI also in model 2 
(Table 3).
Our data are in agreement with previous reporting sug-
gesting a cross-talk among HMGB-1 and inflammatory 
molecules, including CRP. Specifically Kawahara and 
coworkers demonstrated that, through the p38MAPK 
pathway, CRP induces the production of HMGB-1 
in a dose-dependently way [8]. Moreover HMGB-1 
Fig. 1 HMGB-1, OPG, HsCRP, TNF-alpha and IL-6 serum levels in 
diabetic patients with (PAD) and without PAD (WPAD). HMGB-1 high-
mobility group box 1, OPG osteoprotegerin, HsCRP high-sensitivity 
C-reactive protein, TNF-alpha tumor necrosis factor-alpha, IL-6 
Interleukin-6. Statistical test performed with Student’s t test. Data are 
shown as serum levels ± standard deviation. *P < 0.001, +N.S
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up-regulates pro-inflammatory cytokines expression [31, 
32], suggesting that this way contributes to the inflam-
matory process and to atherosclerotic lesion develop-
ment [33, 34]. The role of chronic inflammation in the 
development of PAD and of its complications has been 
extensively investigated in the past. Malmstedt reported 
the role of the receptor for advanced glycation end 
Table 2 Demographic and clinical data of diabetic PAD patients with Fontaine’s II and CLI
Data are number (%) and standard deviation (SD)
CAD coronary artery disease, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
* Statistical test performed with Student’s t test
† Chi square test for categorical values
§ Logistic regression analysis. OR odds ratios, 95% CI 95% confidence intervals
Fontaine’s II CLI P value OR (95% CI)§ P value
(281) (288)
Men/female (n) 166:115 176:112 0.275† 0.91 (0.4–2.1) 0.823
Age (years ± SD) 71.9 ± 3.4 72.7 ± 4.4 0.431* 1.00 (0.9–1.00) 0.476
Smoking (current) (%) 56 (19.9) 154 (53.4) 0.001† 3.43 (2.15–3.65) 0.001
Hypertension (%) 173 (61.6) 182 (63.2) 0.143† 0.89 (0.62–1.04) 0.327
CAD (%) 102 (36.3) 195 (67.7) 0.001† 3.74 (2.49–4.02) 0.001
Diabetes duration (years ± SD) 9.3 ± 3.1 15.7 ± 5.1 0.001† 4.37 (3.07–5.12) 0.001
Total cholesterol (mmol/L) 3.65 (1.12) 5.68 (1.83) 0.001† 2.05 (1.54–3.02) 0.001
HDL-C (mmol/L) 1.15 (1.01) 1.31 (1.09) 0.247† 0.85 (0.69–1.01) 0.296
LDL-C (mmol/L) 1.95 (0.87) 3.25 (1.43) 0.001† 2.69 (1.32–4.12) 0.001
Triglyceride (mmol/L) 1.95 (1.45) 1.93 (1.06) 0.473† 1.32 (0.71–1.58) 0.456
Fast glucose (mmol/L) 6.78 (1.84) 6.97 (2.46) 0.945† 1.02 (0.56–1.34) 1.001
Glycated hemoglobin (%) 7.25 (1.16) 7.33 (1.32) 0.854† 1.00 (0.43–1.15) 0.765
Fig. 2 HMGB-1, OPG, HsCRP and IL-6 serum and severity of PAD 
(Fontaine’s II and Critical Limb Ischemia). HMGB-1 high-mobility group 
box 1, OPG osteoprotegerin, HsCRP high-sensitivity C-reactive protein, 
IL-6 interleukin-6. Statistical test performed with Student’s t test. Data 
are shown as serum levels ± standard deviation. *P < 0.001
Table 3 Multivariable stepwise logistic regression model 
for presence of PAD
Model 1: adjusted for traditional cardiovascular risk factors and established 
inflammatory cytokines; Model 2: adjusted for the risk factors in model 1 plus 
HMGB-1 and OPG
Variable OR (95% CI) P value
Model 1
 Age 1.02 (1.01–1.19) 0.146
 Smoking 36.71 (4.54–179.31) 0.001
 Hypertension 24.91 (5.56–89.65) <0.001
 Hyperlipidemia 12.54 (2.45–28.34) 0.022
 TC 1.56 (1.06–1.94) 0.034
 HDL-C 0.02 (0.01–0.22) 0.001
 LDL-C 9.43 (1.65–74.34) 0.066
 hsCRP 35.32 (7.45–129.22) <0.001
 IL-6 6.01 (2.02–16.02) 0.012
Model 2
 Sex 0.15 (0.02–0.94) 0.097
 Age 1.56 (1.15–1.78) 0.164
 Smoking 66.43 (4.21–654.01) 0.012
 Hypertension 41.12 (6.24–189.54) <0.001
 Hyperlipidemia 8.57 (1.57–49.24) 0.017
 TC 0.05 (0.01–0.43) 0.012
 HDL-C 0.01 (0.00–0.24) 0.001
 LDL-C 13.86 (1.34–153.27) 0.019
 hsCRP 65.89 (8.11–436.53) <0.001
 IL-6 7.87 (2.47–18.04) 0.008
 HMGB-1 12.32 (3.56–23.54) 0.023
 OPG 3.53 (1.54–6.15) 0.019
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products (RAGE), showing that higher circulating lev-
els of an endogenous ligand for RAGE, the pro-inflam-
matory protein S100A12, was associated with increased 
risk for amputation or death and with earlier develop-
ment of PAD [35]. Several circulating inflammatory bio-
markers have been suggested to predict occurrence (i.e. 
Rho-kinase activity, human cartilage glycoprotein-39, 
TWEAK, PON-3, B2M, NO, NOX-2, TGF-β1, TSP-1, 
VEGF) and/or the severity of PAD (i.e. sVCAM-1, MPO, 
NT-proBNP, VEGF, VEGF-A isoforms and MMPs). 
Anyway their validity as reliable clinical markers is still 
debated [36].
Two sources have been proposed to increase HMGB-1 
circulating levels, the local HMGB-1 release promoted by 
damaged immune cells such as monocytes, macrophages, 
endothelial cells cytokine-triggered, or the secretion from 
vascular smooth muscle cells (VSMCs) in atherosclerotic 
lesions [5, 37]. Moreover VSMCs may be both source 
and target of HMGB-1 having been shown VSMCs pro-
liferation following HMGB-1 self-secreted by them. This 
mechanism could explain our observation that HMGB-1 
serum levels strongly correlate with PAD severity. In 
fact, as atherosclerosis goes over, more macrophages 
releasing HMGB-1 are recruited and induce prolifera-
tion and migration of VSMCs that in turn increase their 
self-secretion of HMGB-1 stimulating further their pro-
liferation. This mechanism self-perpetuating can con-
tribute to progression of atherosclerotic lesions [33]. 
Moreover HMGB-1 mRNA expression could be strongly 
up-regulated by inflammatory cytokines such as TNF-
alpha [33]. In our study we have confirmed that serum 
levels of TNF-α, as well IL-6 and HsCRP, are significantly 
increased in diabetic patients with concomitant PAD 
[38, 39]. Similarly in animal studies HMGB-1 has been 
shown play an important role in atherosclerotic process 
exerting pro-atherogenic effects through the modula-
tion of pro-inflammatory mediators, macrophage migra-
tion, and accumulating smooth muscle and immune cells. 
HMGB-1 neutralization also reduces diet-induced ather-
osclerosis in apolipoprotein E-deficient mice [40]. More-
over high HMGB-1 serum levels have been reported be 
associated with CAD in patients with and without T2D 
and they were gradually correlated with the severity of 
coronary artery stenosis [41, 42].
OPG and its role in endothelial dysfunction
HMGB-1 is a bone-active cytokine and on multiple 
murine bone cells culture recombinant protein (rHMGB-
1) enhanced the RANKL/OPG steady state mRNA ratio 
and augmented the release of TNF-alpha and IL-6 in 
osteoblastogenic bone marrow stromal cell (BMSC) [15]. 
In our study we also measured circulating levels of OPG 
establishing a positive correlation between serum OPG 
levels and the occurrence of PAD in diabetic patients 
(Fig. 1). Moreover OPG has resulted a significant predic-
tor of disease severity (Fig. 2).
The association between OPG and atherosclerosis in 
CAD is quite well studied. OPG has been reported an 
independent risk factor for development and progression 
of atherosclerosis in patients with CAD [43]. Also OPG 
predicted early carotid atherosclerosis in patients with 
CAD [44]. In our study, as shown in Table 1, CAD occur-
rence is similar between the two groups (P = 0.294), thus 
it is to be ruled out it as a possible confounder. Studies 
investigating the role of OPG in PAD have done con-
trasting and uncertain results. While some of them 
did not find any serum OPG level increase in patient 
with PAD [19, 20], others showed a positive correla-
tion between circulating OPG and severity of PAD [18] 
or reported OPG as an independent predictor of PAD 
[33]. More recently two studies investigated the associa-
tion between OPG and PAD in T2D patients [45, 46] and 
demonstrated that OPG concentrations are significantly 
increased in T2D patients having PAD in comparison 
with T2D without PAD. However they have focused on 
a smaller and younger population of patients, and no 
data were available regarding CAD occurrence as in our 
report. A recent our report showed a significant posi-
tive association between OPG serum levels and occur-
rence and severity of PAD in a population of T2D [23]. 
However in this study, patients affected by PAD also had 
a significantly higher occurrence of CAD compared to 
diabetic patients without PAD, so it could not be ruled 
out as possible bias to investigations. Of interest, we also 
reported for the first time that fibroblast growth factor 23 
(FGF23) is a predictor of PAD occurrence and severity, 
moving from a previous report of our group [47] in which 
we suggested the association between FGF23 and OPG 
in patients with unstable carotid plaques, thus underly-
ing the role of the two molecules in the development of 
atherosclerosis owing to their contribute to vascular cal-
cification. To corroborate the involvement of FGFs fam-
ily members in the early stage of atherosclerosis, Zhang’s 
group [48] observed that circulating FGF21, an emerging 
metabolite regulating glucose and lipid metabolism, is 
directly associated with lower extremity atherosclerosis 
disease. They also found an association between serum 
FGF21 levels and carotid intima thickness in the female 
group, accounting maybe for a gender-specific effect. All 
together these studies took in account the endothelial 
dysfunction, an early and important trigger of athero-
genesis, as mechanism responsible for PAD development 
and worsening. In this direction an interesting signifi-
cant association of high OPG was found with the non-0 
blood groups in PAD patients, considering that non-0 
blood group subjects have a well-established higher risk 
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of developing thrombotic episode of venous or arterial 
origin [49].
Whether OPG plays a causal role in mediating or pro-
tecting against vascular injury is presently unclear. An 
atheroprotective effect of OPG could be related to its 
anti-calcification function or due to its action as a decoy 
receptor for the receptor activator of nuclear factor-B 
ligand (RANK-L) and the TNF-related apoptosis induc-
ing ligand (TRAIL) by which it blocks their subsequent 
pro-inflammatory and pro-apoptotic effects [50, 51]. In 
particular OPG has been identified as an in  vitro sur-
vival factor for endothelial cells [52]. On the other hand 
recent evidence supports a pro-atherosclerotic role for 
OPG including its capacity to enhance the expression of 
endothelial cell adhesion molecules promoting infiltra-
tion of leukocytes and monocytic cells [53]. However, 
there are some frequently ignored aspects like polyvas-
cular atherosclerosis which might influence OPG levels 
[19]. Furthermore, OPG might contribute to endothelial 
dysfunction by reducing the nitric oxide synthase protec-
tive pathway by blocking RANK-L [54]. A longitudinal 
prospective study is needed to clarify the causal relation-
ship among HMGB-1, OPG and PAD.
Limitations
There are some limitations in the present study. First, we 
developed a case–control study, thus survival and enroll-
ment bias should be considered. Second, we collected 
data from an European cohort having other cardiovas-
cular diseases. Also, comorbidities might represent con-
founding factors and our findings are not generalizable to 
other age groups or ethnicities. So our observations need 
to be confirmed in larger populations and different ethnic 
groups. Finally the influence of other pro-inflammatory 
molecules such as myeloperoxidase, soluble adhesion 
molecules, sCD40 and matrix metalloproteinases did not 
evaluate in this study.
Conclusions
The present study demonstrated that HMGB-1 and OPG 
serum levels are statistically and independently associ-
ated with occurrence and clinical severity of PAD in an 
Italian population affected by T2D. The understanding of 
pathophysiological mechanisms and of molecular path-
ways responsible for HMGB-1 and OPG involvement in 
atherosclerosis disease may provide us new therapeutic 
weapons to manage diabetic complications and morbidi-
ties. Furthermore the measurement of these two serum 
markers could be useful as diagnostic and prognostic 
markers of PAD in diabetic patients.
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